COLON SPECIFIC DELIVERY OF EUDRAGIT E-100 AND EUDRAGIT-FS30D COATED TABLETS OF LEFLUNOMIDE USING CHITOSAN-CHONDROITIN SULPHATE INTERPOLYMER COMPLEX

  • Reetika Chopra Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar 143005, India
  • Kammal Preet Kaur Guru Nanak Dev University
  • Neena Bedi Guru Nanak Dev University

Abstract

Objectives: In the present study, site specific colonic drug delivery system was developed on the principles of the combination of pH and microbially triggered controlled system.

Methods: The basic design consists of chitosan-chondroitin sulphate inter-polymer complex containing leflunomide. The core tablet was enteric coated with Eudragit E-100 so that colon specific drug release can be achieved. The leflunomide, chitosan (CH), chondroitin sulphate (ChS), chitosan-chondroitin sulphate inter-polymer complex (CH-ChS IPC) were characterized by Fourier Transform Infrared Spectroscopy (FT-IR). In vitro drug release study was conducted using sequential dissolution technique at 0.1 N HCl buffer (simulated gastric fluid), phosphate buffer pH 7.4 (simulated intestinal fluid) and finally in phosphate buffer pH 6.8 (simulated colonic fluid) with or without rat caecal content.

Results: FTIR studies confirmed that there was no interaction between drug and polymer. Tablets coated with Eudragit E-100 with different coat weights showed less than 10% of drug release in the stomach whereas same tablets showed 13.42%, 9.5%, 12.37% and 12.83% release of drug in phosphate buffer pH 7.4 and95.43%, 90.31%, 98.44% and 96.64% release of drug in phosphate buffer pH 6.8. Histopathology of rat colon after administration of Eudragit E-100 coated tablets containing chitosan-chondroitin sulphate inter-polymer complex revealed the marked reduction in acetic acid induced colitis in the test group.

Conclusion: The present study confirmed that coating with Eudragit E-100 delivered the leflunomide to colon in highest efficacy with the least toxic effects of an anti-inflammatory therapy.

 

Keywords: Chitosan, Chondroitin sulphate, Eudragit E-100, Colon, Leflunomide

Downloads

Download data is not yet available.

References

1. Watts PJ, Illum L. Colonic drug delivery and opportunities. Indian J Pharm Sci 1997;23:893-913.
2. Mrsny RJ. The colon as a site for drug delivery. J Controlled Release 1992;22:15-34.
3. Edwards C. Physiology of the colorectal barrier. Adv Drug Delivery Rev 1997;28:173-90.
4. Wilding IR, Davis SS, Pozziand F, Gazzangia A. Enteric coated timed released systems for colonic targeting. Int J Pharm 1994;111:99-102.
5. Holtman MH, Gerts AL, Weinman A, Galle PR, Neuroth MF. Treatment of Crohn’s disease with leflunomide as second line immune suppression: phase I open label; trial on efficacy, tolerability and safety. Dig Dis Sci 2008;53:1025-32.
6. Kaur G, Rana V, Jain S, Tiwary A. Colon delivery of budesonide: Evaluation of chitosan-chondroitin sulphate interpolymer complex. AAPS Pharm Sci 2010;11:36-45.
7. Amruktar JR, Gattani SG. Chitosan-chondroitin sulphate based matrix tablets for colon specific drug of indomethacin. AAPS Pharm Sci 2009;10:670-7.
8. Meiling Q, Peng W, Dezheng W. A novel pH and time-dependent system for colonic drug delivery. Drug Dev Ind Pharm 2003;29:661-7.
9. Van den Mooter G, Maris B, Samyn C, Augustijns P. Use of azo polymers for colon specific drug delivery. J Pharm Sci 1997;86:1321-7.
10. United States Pharmacopoeial Convention, Inc. The United States Pharmacopoeia XXX. The National Formulary XXV. United States Pharmacopoeial Convention, Inc. Rockville, MD. U. S. A; 2007. p. 1798-800.
11. Takaya T, Niwa K, Muroka M, Ogita I, Nagai N, Yano R, Kimura G, et al. Importance of dissolution process on systemic availability by colon delivery system. J Controlled Release 1998;50:111-22.
12. Okasyasu I, Yamada MS, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterol 1990;98:694-702.
13. Elson CO, Sartor RB, Tennyson GS, Riddell RH. Experimental models of inflammatory bowel disease. Gastroenterol 1995;109:1344-67.
14. Leoplad CS, Eikel D. Basic coating polymers for the colon-specific drug delivery in inflammatory bowel disease. Drug Dev Ind Pharm 2000;26:12391-6.
15. Chen X, Li W, Zhong W, Lu Y, Yu T. pH sensitivity and ion sensitivity of hydrogels based on complex-forming chitosan/silk fibroin interpenetrating polymer network. J Appl Polym Sci 1997;5:2257–62.
16. Raghavan CV, Muthulingam C, Jenita JA, Ravi TK. An in vitro and in vivo investigation into the suitability of bacterially triggered delivery system. Chem Pharm Bull 2002;50:892-5.
17. Kshirsagar SJ, Bhalekar MR, Umap RR. In vitro-In vivo comparison of two pH sensitive Eudragit polymers for colon specific drug delivery. J Pharm Sci Res 2009;1:61-70.
18. Gupta BK, Pal RM, Chakraborty M, Debnath R. Design, evaluation and optimization of microcapsules of leflunomide with Eudragit RL-100 and Eudragit RS-100 by solvent evaporation technique. Asian J Pharm Sci 2009;3:309-13.
19. Rubinstein A. Microbially controlled drug delivery to the colon. Biopharm Drug Dispos 1990;11:465-75.
20. Cummings JH, Macfarlane GT. The control and consequences of bacterial fermentation in the human colon. J Bacteriol 1991;70:443-59.
Statistics
297 Views | 1783 Downloads
How to Cite
Chopra, R., K. P. Kaur, and N. Bedi. “COLON SPECIFIC DELIVERY OF EUDRAGIT E-100 AND EUDRAGIT-FS30D COATED TABLETS OF LEFLUNOMIDE USING CHITOSAN-CHONDROITIN SULPHATE INTERPOLYMER COMPLEX”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 7, no. 9, July 2015, pp. 286-91, https://innovareacademics.in/journals/index.php/ijpps/article/view/6969.
Section
Original Article(s)